(3-iodo-benzyl)-dimethyl-amine | 141189-59-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-iodo-benzyl)-dimethyl-amine
• 英文别名: N-(3-Iodobenzyl)-N,N-dimethylamine；1-(3-iodophenyl)-N,N-dimethylmethanamine
• CAS: 141189-59-5
• 化学式: C₉H₁₂IN
• mdl: MFCD06797851
• 分子量: 261.105
• InChiKey: WYNJGHRFIPXFMC-UHFFFAOYSA-N

物化性质

• 熔点：
  128-130 °C
• 沸点：
  249.3±23.0 °C(Predicted)
• 密度：
  1.553±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (3-iodo-benzyl)-dimethyl-amine 、 2-溴苯乙酮 在 苯 作用下， 生成 (3-iodo-benzyl)-dimethyl-phenacyl-ammonium; bromide
  参考文献：
  名称：

  7.季铵盐的降解。第四部分：取代苄基的相对迁移速度

  摘要：

  DOI：

  10.1039/jr9320000055
• 作为产物：
  描述：

  N,N-二甲基乙酰胺 、 3-碘苯甲醛 在 溶剂黄146 、 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 反应 1.67h， 以90%的产率得到(3-iodo-benzyl)-dimethyl-amine
  参考文献：
  名称：

  [EN] 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS
  [FR] DÉRIVÉS AMIDES D'ACIDE 6-(4-HYDROXYPHÉNYL)-3-STYRYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIQUE EN TANT QU'INHIBITEURS DE KINASE

  摘要：

  本发明涉及具有以下式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4和R5如下所示。式I的化合物是激酶抑制剂，可用于治疗与糖尿病及糖尿病并发症相关的疾病，例如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，该发明还涉及将式I的化合物用作药物中的活性成分，以及包含它们的药物组合物。

  公开号：

  WO2013037390A1

文献信息

• [EN] HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES EN TANT QU'ANTAGONISTES DE MGLU5
  申请人：RECORDATI IRELAND LTD

  公开号：WO2010089119A1

  公开（公告）日：2010-08-12

  Novel compounds I (R1 = a mono or bicyclic C1-C9 heterocyclic group containing from 1 to 3 heteroatoms chosen from N, O and S, a phenyl group, a C3-C6 cycloalkyl group, or a C3-C6 cycloalkenyl group, each of which may optionally be substituted; R2 = a mono or bicyclic C1-C9 heterocyclic group containing from 1 to 3 heteroatoms chosen from N, O and S, or a phenyl group, each of which may optionally be substituted; R3 = H, F, CN or an optionally substituted C1-C6 alkyl group, m is 0, 1 or 2; and n is 0, 1 or 2) are antagonists selective for the metabotropic mGlu5 receptor, useful for the treatment of neuromuscular dysfunction of the lower urinary tract in a mammal. Further uses include the treatment of migraine; gastroesophageal reflux disease (GERD); anxiety disorder; abuse, substance dependence and substance withdrawal disorder; neuropathic pain disorder; and fragile X syndrome disorders.

  新化合物 I（其中 R1 = 包含从 1 到 3 个异原子（N、O 和 S）中选择的单环或双环 C1-C9 杂环基团、苯基、C3-C6 环烷基基团或 C3-C6 环烯基基团，每个基团可选择性地被取代；R2 = 包含从 N、O 和 S 中选择的 1 到 3 个异原子的单环或双环 C1-C9 杂环基团或苯基，每个基团可选择性地被取代；R3 = H、F、CN 或可选择性地被取代的 C1-C6 烷基基团，m 为 0、1 或 2；n 为 0、1 或 2）是选择性拮抗剂，用于治疗哺乳动物下尿道神经肌肉功能障碍的代谢型 mGlu5 受体。进一步的用途包括治疗偏头痛；胃食管反流病（GERD）；焦虑症；滥用、物质依赖和物质戒断障碍；神经病性疼痛障碍；以及脆性 X 综合征障碍。
• 6-(4-HYDROXY-PHENYL)-3-STYRYL-1H-PYRAZOLO[3,4-b]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS
  申请人：LOEHN Matthias

  公开号：US20130065894A1

  公开（公告）日：2013-03-14

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R 1 , R 2 , R 3 , R 4 and R 5 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的吡唑啉[3,4-b]吡啶化合物，其中R1、R2、R3、R4和R5如下所示。式I的化合物是激酶抑制剂，可用于治疗与糖尿病及糖尿病并发症相关的疾病，如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变等。此外，该发明还涉及式I的化合物的用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。
• 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：Loehn Matthias

  公开号：US08846712B2

  公开（公告）日：2014-09-30

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula I, in which R1, R2, R3, R4 and R5 are defined as indicated below. The compounds of the formula I are kinase inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula I, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的吡唑并[3,4-b]吡啶化合物，其中R1、R2、R3、R4和R5如下所示。式I的化合物是激酶抑制剂，并且可用于治疗与糖尿病和糖尿病并发症相关的疾病，例如糖尿病肾病、糖尿病神经病和糖尿病视网膜病变。此外，本发明还涉及使用式I的化合物，特别是作为药物的活性成分以及包含它们的制药组合物。
• NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS
  申请人：Leonardi Amedeo

  公开号：US20100317630A1

  公开（公告）日：2010-12-16

  The invention is directed to methods of using antagonists selective for the metabotropic mGlu5 receptor to treat conditions of neuromuscular dysfunction of the lower urinary tract in a mammal. Provided are methods of treating a mammal suffering from a condition of neuromuscular dysfunction of the lower urinary tract by administering a selective mGlu5 antagonist. The selective mGlu5 antagonist may be administered alone or in combination with one or more additional therapeutic agents for treating such a condition. Also provided are methods of identifying selective mGlu5 antagonists that are useful for treating neuromuscular dysfunction of the lower urinary tract in a mammal. Methods for treating migraine and gastroesophageal reflux disease (GERD) using selective mGlu5 antagonists are also disclosed.

  本发明涉及使用选择性拮抗剂对代谢型mGlu5受体的方法，以治疗哺乳动物下尿道神经肌肉功能障碍的病症。提供了通过给予选择性mGlu5拮抗剂治疗患有下尿道神经肌肉功能障碍病症的哺乳动物的方法。选择性mGlu5拮抗剂可以单独或与一种或多种其他治疗剂联合使用以治疗此类病症。还提供了用于治疗偏头痛和胃食管反流病（GERD）的选择性mGlu5拮抗剂的方法。同时提供了用于鉴定对治疗哺乳动物下尿道神经肌肉功能障碍有用的选择性mGlu5拮抗剂的方法。
• 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
  申请人：SANOFI

  公开号：EP2567959A1

  公开（公告）日：2013-03-13

  The present invention relates to pyrazolo[3,4-b]pyridine compounds of the formula, in which R1, R2, R3, R4 and R5 are defined as indicated below. The compounds of the formula are kinase C (PKC) inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式中的吡唑并[3,4-b]吡啶化合物、 其中 R1、R2、R3、R4 和 R5 的定义如下所示。式中化合物是激酶 C (PKC) 抑制剂，可用于治疗与糖尿病和糖尿病并发症有关的疾病，例如糖尿病肾病、糖尿病神经病变和糖尿病视网膜病变。本发明还涉及式化合物的用途，特别是作为药物的活性成分，以及包含它们的药物组合物。